ClinicalTrials.gg
CompletedNCT03411915Updated May 10, 2022

A Study of XmAb®18087 in Subjects With NET and GIST

A Phase 1 interventional study of XmAb18087 in Neuroendocrine Tumor and Gastrointestinal Neoplasm, sponsored by Xencor, Inc.. Completed at 16 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-05-10.

Sponsored by Xencor, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2021, 5 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 218 studies in Neuroendocrine Tumors with a site in United States — 44 open to participants now, 76 under way, 10 of them phase 3. Neuroendocrine Tumors · United States.

Enrollment
69th of 189
62 · median 36
Started
2018
with 12 others
Phase 1
47 of 218
9 open now
Registered
122nd of 218
by date

Among the 218 studies in Neuroendocrine Tumors with a site in United States, this one is the 69th largest by enrollment of the 189 interventional ones that give a count, is one of 13 that started in 2018, is one of 47 in phase 1, and was the 122nd registered.

Neuroendocrine Tumors

543 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

44 of the 218 studies in Neuroendocrine Tumors with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Neuroendocrine Tumors studies recruiting now, 73 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies in Neuroendocrine Tumors with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, multiple dose, ascending dose escalation study; to define a MTD/RD and regimen consisting of a first "priming" dose and escalated subsequent doses of XmAb18087; to describe safety and tolerability; to assess PK and immunogenicity; and to preliminarily assess anti-tumor activity of XmAb18087 in subjects with advanced NET or GIST.

The study will enroll dosing cohorts to establish a MTD/RD and regimen in subjects with advanced NET or GIST, then enroll additional subjects into separate NET and GIST expansion cohorts to collect additional data on safety and potential efficacy of XmAb18087.

03

Conditions studied

  • Neuroendocrine Tumor
  • Gastrointestinal Neoplasm

Keywords

  • NET
  • GIST
  • DUET-1
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed well differentiated low or intermediate grade (World Health Organization [WHO] Grade 1 or 2) NET of pancreatic, gastrointestinal, lung, or undetermined origin that is locally advanced or and has progressed within the past 12 months
  • Histologically confirmed GIST that is locally advanced or metastatic
  • NET and GIST tumors must be unresectable
  • NET subjects must have progressed on or been ineligible for treatment with somatostatin analogues (SSA) and at least one other FDA-approved targeted therapy (everolimus or sunitinib).
  • GIST subjects must have previously received all FDA-approved therapies (imatinib mesylate, sunitinib malate, and regorafenib) for which they are eligible
  • Must have disease measurable by 1.1 criteria using either computed tomography (CT) or magnetic resonance imaging (MRI) scan
  • (ECOG) performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of high-grade (WHO Grade 3) or poorly differentiated NET; high-grade neuroendocrine carcinoma; large cell neuroendocrine carcinoma, small cell carcinoma, or mixed small and large cell carcinoma.
  • Subjects currently receiving anti-cancer therapies (other than SSAs, which may continue).
  • Subjects who have received anti-cancer therapies within 2 weeks of the start of study drug (including chemotherapy, radiation therapy, immunotherapy, etc.).
  • Must not be experiencing a Grade 3 or 4 toxicity from previous anti-cancer treatment
  • Must not be receiving other anti-cancer therapies (except somatostatin analogues, which may be allowed)
  • Must not have poorly controlled diabetes mellitus, known central nervous system involvement by malignant disease or insufficient bone marrow, renal, or hepatic function
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    XmAb18087

    XmAb18087 administered on days 1, 8, 15, and 22 of each 28-day cycle for a total of 3 cycles

    Biological: XmAb18087

Interventions

  • BiologicalXmAb18087

    monoclonal bispecific antibody

06

What researchers measure

Primary outcomes

  1. Determine the safety and tolerability profile of XmAb18087

    Treatment-related adverse events as assessed by CTCAE v4.03

    Time frame: 84 Days

  2. Identify the maximum tolerated dose (MTD) and/or recommended dose (RD) and schedule of XmAb18087

    Establishing a safe and tolerable dose of XmAb18087 administered by intravenous (IV) dosing in NET and GIST patients

    Time frame: 84 Days

07

Study locations

16 sites
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
  • City of Hope Medical Center
    Duarte, California 91010, United States
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
    Los Angeles, California 90048, United States
  • Stanford Cancer Center
    Palo Alto, California 94304, United States
  • University of Colorado, Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • H. Lee Moffitt Cancer Center & Research Institute
    Tampa, Florida 33612, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern Medicine
    Chicago, Illinois 60611, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • James Cancer Center
    Columbus, Ohio 43210, United States
  • University of Pennsylvania, Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Virginia
    Charlottesville, Virginia 22908, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Oct 2021, 45 months.

Of 54 phase 1 interventional studies under Neuroendocrine Tumors, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 75. This study's 45 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2018
First posted
Jan 26, 2018
StartActual
Jan 22, 2018
Primary completionActual
Oct 26, 2021
CompletionActual
Oct 26, 2021
Last update
May 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03411915
Lead sponsor
Xencor, Inc.
Collaborators
ICON plc
Responsible party
Sponsor
First posted
Jan 26, 2018
Start date
Jan 22, 2018
Primary completion
Oct 26, 2021
Completion
Oct 26, 2021
Last update
May 10, 2022

Study contacts

Zequn Tang, MD, PhD
study director · Senior Medical Director, Clinical Development, Xencor

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion